New M3AD Study Launches Advanced Platform to Predict and Understand Alzheimer's Disease
A groundbreaking new study, spearheaded by Columbia University Mailman School of Public Health in collaboration with Vagelos College of Physicians and Surgeons, the School of Nursing, the University of Miami, and the University of Chicago, has unveiled the M3AD Study and Real-World Data Metaplatform. This ambitious initiative is poised to revolutionize the prediction and understanding of Alzheimer's disease and related dementias (AD/ADRD) through the innovative use of large-scale clinical data. The comprehensive findings have been officially published in the esteemed journal Alzheimer's & Dementia.
The M3AD platform aims to advance the prediction and understanding of Alzheimer's disease and related dementias (AD/ADRD) using large-scale clinical data.
Powering Prediction with Real-World Data
The M3AD platform leverages electronic health records (EHRs) from approximately 60,000 individuals diagnosed with AD/ADRD across three major U.S. cities. Its core design focuses on tracking the long-term interactions of multiple chronic diseases, behaviors, and social conditions that collectively influence dementia risk. This novel approach moves beyond traditional studies by analyzing complex health trajectories simultaneously, promising to significantly improve predictions of dementia risk and progression.
According to Moise Desvarieux, associate professor of Epidemiology and the study's corresponding author, the platform's strength lies in its ability to integrate and harmonize electronic health records from nearly 10 million patients across major health systems in New York City, Chicago, and Miami. This vast dataset specifically includes the 60,000 patients with AD/ADRD mentioned earlier.
Addressing Multimorbidity in Dementia
Dementia poses a significant public health challenge, affecting over 7.2 million older Americans. A critical factor often overlooked is multimorbidity—the presence of two or more chronic diseases—which impacts nearly 90 percent of adults over age 60. The M3AD initiative directly challenges the traditional view of dementia as an isolated disease. Instead, it recognizes dementia as the complex culmination of interactions among various health factors.
"Analyzing longitudinal clinical histories from EHRs may help identify previously unrecognized early warning signs of dementia within the broader context of patients' lives," notes George Hripcsak, co-author and professor of biomedical informatics at Columbia.
A Consortium for Advanced Analytics
The three-city consortium represents a powerful alliance in data collection and analysis. It brings together data from:
- NewYork-Presbyterian Hospital Clinical Data Warehouse: Providing 32 years of data from approximately 6 million patients, including 33,000 with AD/ADRD.
- University of Chicago Clinical Research Data Warehouse: Contributing data from over 2 million patients, with 11,000 having AD/ADRD.
- University of Miami Health System: Adding data from about 1.4 million patients, including 13,000 with AD/ADRD.
These combined datasets offer a rich resource representing a multiethnic population, which is crucial for researching dementia risk across diverse groups. The project also employs advanced analytical methods, such as cutting-edge machine-learning models and a federated platform designed for collaborative, privacy-preserving data analysis. Future expansions of the platform are anticipated to integrate imaging, genetic information, and novel biomarkers.
Tatjana Rundek, director of the Evelyn F. McKnight Brain Institute at the University of Miami, emphasizes, "Understanding and preventing dementia requires a holistic view of the individual's health trajectory." She states that the platform is designed to uncover early signs of dementia and transform real-world care.
Predictive Tools and Prevention Research
Central to the platform are its innovative predictive tools, such as the Electronic Health Record Risk of Alzheimer's and Dementia Assessment Rule (eRADAR). This sophisticated algorithm is specifically designed to identify individuals with undiagnosed dementia who may require further clinical evaluation.
Beyond identification, the platform will empower researchers to test prevention hypotheses in real-world populations. This includes examining how critical factors like smoking cessation, maintaining a healthy weight, and effective blood-pressure control in middle age influence later cognitive decline.
An Interdisciplinary Approach to Uncover Risks
By linking clinical data with crucial neighborhood-level contextual and social factors, the M3AD initiative fosters a truly interdisciplinary research environment. This powerful connection bridges fields such as epidemiology, neurology, biostatistics, informatics, machine learning, and social sciences, enabling a deeper examination of how social and environmental conditions shape Alzheimer's risk and progression.
The researchers concluded that this multidisciplinary approach significantly enhances risk prediction, guides clinical management, and evaluates future treatments for Alzheimer's disease in real-world settings.
Funding Support
The study received vital support from the National Institute on Aging (grant R56AG082167) and pilot funding from the Mailman Centennial Grand Challenges in Public Health. The authors reported no financial conflicts of interest.